...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: One more thing to remember is...

per the MIC "...the Purchase Price is subject to adjustment...". Now they are talking 65.6% and 34.4%...maybe it will be 70-30, or 75-25...it should not matter in the least to any current Zenith shareholder.

You still own the same number of shares and therefore you also own a relative piece of 100% of whatever Zenith Epiginetics Corp. (soon to become Zenith Capital Corp.) owns, including Zenith Epiginetics Ltd. (Newco)...which remains a private company.

This certainly is getting frustrating. I understand that people's minds all work and think differently but this is turning into a circus.

Trying what may be my last post now on a laptop. Apparently you really gotta have the paragraphs. I hope this works.

GLTA

PVLee

Share
New Message
Please login to post a reply